Cybin Inc. (NEO: CYBN) Files Patent Designed to Bolster IP Psychedelic Molecule, Delivery Mechanism Portfolio 

  • Company files 12th patent to strengthen proprietary IP program
  • Cybin believes treatments can decrease costs, increase access to important therapeutics
  • Patent provides wide range of benefits in Cybin’s four drug candidate program

Cybin (NEO: CYBN) (OTCQB: CLXPF) has filed a new provisional patent application designed to strengthen the company’s ongoing drug candidate programs (https://ibn.fm/9V5sv). Cybin, a biotechnology company focused on progressing psychedelic therapeutics, is focused on expanding its four active drug programs targeting depression, addiction and other psychiatric conditions alongside its growing portfolio of 50+ proprietary psychedelic molecules.

“By continuing to innovate in directions to enhance the patient experience and reducing clinical observation times, we believe our treatments can decrease costs and increase the capacity of medical professionals in this field, which will promote increased access to these important therapeutics for those in need,” said Cybin CEO Doug Drysdale.

According to the announcement, the patent — the 12th filed by the company— has a provisional application including disclosures directed to innovate oral dosage forms thought to provide therapeutic advantages in addressing Cybin’s target indications over the current options. The application is also synergistic with other patent applications filed by Cybin that are also related to a delivery technology covering various chemically synthesized psychedelic molecules, which is expected to provide faster onset times in a similar route to intravenous treatments.

In addition, Cybin noted that the patent application strengthens its portfolio relative to deuterated psychedelic molecules and analogues that are designed to produce greater stability, better potency, more control over duration and greater bioavailability than other forms of these molecules. Finally, the patent application disclosures related to more rapid therapeutic onset as well as reduced duration and side effects are intended to decrease the clinical costs of administration resulting from shortened clinical observation time.

Cybin filed the patent with the U.S. Food and Drug Administration, an application that reveals novel compositions intended to have improved pharmacokinetic profiles while retaining key efficacy measures of the original molecules; the application also outlines novel methods of deploying Cybin’s original compositions with more rapid therapeutic onset of the company’s psychedelic tryptamine at the same time while reducing the number and duration of psychedelic and therapeutic effects.

Cybin’s four drug programs include CYB001, a sublingual psilocybin formulation designed for patients suffering from major depressive disorder; CYB003 and CYB004, both proprietary deuterated psychedelic tryptamine designed for treatment of alcohol use disorder and other therapy resistant psychiatric disorders; and CYB005, a phenethylamine targeting psychiatry and neurology treatment.

Cybin Corp., a leading biotech company focused on progressing psychedelic therapeutics, is on a mission to revolutionize mental health care. The company is focused on progressing psychedelic therapeutics by utilizing proprietary drug-discovery platforms, innovative drug-delivery systems, novel formulation approaches and treatment regimens for psychiatric disorders.

For more information, visit the company’s website at www.Cybin.com.

NOTE TO INVESTORS: The latest news and updates relating to CYBN are available in the company’s newsroom at https://ibn.fm/CYBN

About PsychedelicNewsWire

PsychedelicNewsWire (PNW) is a specialized content distribution company that (1) aggregates and distributes news and information on the latest developments in all aspects and advances of psychedelics and their use, (2) creates PsychedelicNewsBreaks designed to quickly update investors on important industry news, (3) leverages a team of expert editors to enhance press releases for maximum impact, (4) assists companies with the management and optimization of social media across a range of platforms, and (5) delivers unparalleled corporate communication solutions. PNW stays abreast of the latest information and has established a reputation as the go to source for coverage of psychedelics, therapeutics and emerging market opportunities. Our team of seasoned journalists has a proven track record of helping both public and private companies gain traction with a wide audience of investors, consumers, media outlets and the general public by leveraging our expansive dissemination network of more than 5,000 key syndication outlets. PNW is committed to delivering improved visibility and brand recognition to companies operating in the emerging markets of psychedelics.

To receive instant SMS alerts, text “Groovy” to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.PsychedelicNewsWire.com

Please see full terms of use and disclaimers on the PsychedelicNewsWire website applicable to all content provided by PNW, wherever published or re-published: https://www.PsychedelicNewsWire.com/Disclaimer

Do you have questions or are you interested in working with PNW? Ask our Editor

PsychedelicNewsWire (PNW)
San Francisco, California
www.PsychedelicNewsWire.com
415.949.5050 Office
Editor@PsychedelicWire.com

PsychedelicNewsWire is part of the InvestorBrandNetwork.

Archives

Select A Month

PsychedelicNewsWire Currently Accepts

Bitcoin

Bitcoin

Bitcoin Cash

Bitcoin Cash

Doge Coin

Dogecoin

Ethereum

Ethereum

Litecoin

Litecoin

USD Coin

USD Coin

Contact us: 415.949.5050